Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Amar Murugan, its Senior Vice President, General Counsel.The compensation committee of Atara’s Board of Directors granted Mr. Murugan a stock option to purchase 110,000 shares of Atara’s common stock effective as of April 20, 2020, and restricted stock units to acquire 55,000 shares of Atara’s common stock effective as of April 20, 2020. The stock option and restricted stock units were granted as an inducement material to Mr. Murugan entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The stock option has a ten-year term and an exercise price of $8.20, equal to the per share closing price of Atara's common stock as reported by Nasdaq on April 20, 2020. The a
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-TransAcquire Media Monitor
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.MarketBeat
- Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceBusiness Wire
ATRA
Earnings
- 11/12/24 - Beat
ATRA
Sec Filings
- 12/23/24 - Form 8-K
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- ATRA's page on the SEC website